Methotrexate Gry (Methotrexate Disodium)

Methotrexate blocks the enzyme dihydrofolate reductase, which is needed to regenerate tetrahydrofolate, a co‑factor for DNA and RNA synthesis. This interruption reduces the production of nucleotides, limiting the ability of rapidly dividing cells—such as immune cells and cancer cells—to replicate and survive.

The dose of Methotrexate Gry is individualized by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and treatment goals. Dosing regimens vary widely, so patients should follow the exact schedule and amount prescribed by their healthcare provider.

Methotrexate Gry is generally contraindicated in pregnancy because it can cause fetal malformations and miscarriage. It is also not recommended while breastfeeding, as it may be excreted in milk and affect the infant. Women of child‑bearing potential should use effective contraception and discuss risks with their physician.

To order Methotrexate Gry, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed) and any required import documentation.

Methotrexate Gry shares the core mechanism of folate antagonism with other antimetabolites such as pemetrexed, but it is distinguished by its broader approved indications, including both autoimmune diseases and several cancers. Its dosing flexibility and extensive clinical experience make it a common first‑line choice, whereas newer agents may offer different toxicity profiles or target specific tumor types.

Methotrexate Gry must be stored at 2‑8 °C in a refrigerator, protected from light. The product should remain in its original packaging to guard against moisture and should never be frozen or shaken. Prior to administration, inspect the solution for particulate matter and ensure it is at room temperature if required by the infusion protocol.

Methotrexate Gry is given by intravenous infusion, typically over a period ranging from 15 minutes to several hours depending on the indication and dose. Administration is performed by qualified healthcare professionals in a clinical setting, with appropriate monitoring of vital signs and laboratory parameters before, during, and after the infusion.

The most serious risks include severe bone‑marrow suppression leading to pancytopenia, life‑threatening liver injury, acute renal failure, and pulmonary toxicity such as interstitial pneumonitis. Patients should be closely monitored for signs of infection, abnormal liver or kidney tests, and respiratory symptoms, and treatment should be adjusted or discontinued if severe toxicity occurs.

Methotrexate Gry should be avoided in individuals with known hypersensitivity to methotrexate or any component of the formulation, severe renal or hepatic impairment, uncontrolled infections, and in pregnant or breastfeeding women. It is also contraindicated in patients with pre‑existing pulmonary disease that could be exacerbated by the drug.